Jeudi du PSCC #19 : In Vivo CAR

Don't miss the next "jeudi du PSCC" event on the topic: In Vivo CAR

With:

• Silvia MENEGATTI (Cell Action, Institut Curie)

• Christopher BORGES (Sanofi)

• Sofia ARNAL (AdBio Partners)

  
  

Trained as a pharmacist, Silvia Menegatti holds a PhD in Immunology from Institut Pasteur, where she worked on TNF blockade in immune-mediated inflammatory diseases. She then completed a postdoctoral fellowship at Institut Curie (Sebastian Amigorena’s team), focusing on genome-wide CRISPR–Cas9 screens to improve allogeneic CAR-T cells. Since 2024, she is Head of R&D at CellAction, leading multiple projects in cell therapy.

Christopher Borges, PhD, is Head of Non-Viral Gene Therapy and Genome Engineering at Sanofi. He leads the development of integrated non-viral gene editing platforms, enabling the delivery of therapeutic nucleic acids and in vivo genome engineering approaches, including CAR-T therapies. Previously at Editas Medicine, he worked on CRISPR-based engineering across multiple immune cell types. He holds a PhD in Immunology from Harvard University and has authored numerous publications and patents.

Sofia Arnal joined AdBio Partners in 2021. She combines a background as a pharmacist with strong expertise in pharmaceutical R&D and a business degree. Prior to joining AdBio, she contributed to the development of innovative biotech approaches at Institut Pasteur and has experience across the pharmaceutical industry, public hospitals, and academic research.

👉 This PSCC Thursday event is organized in collaboration with UNITC.

On-site & online